Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary ...

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Gossamer Bio (GOSS – Research Report). The associated ...

This can damage lung tissue, leading to reduced lung function and, in extreme cases, a condition called pulmonary fibrosis, where scar tissue forms in the lungs and causes breathing difficulties.

With a focus on innovation, patient-centered care, and collaboration, Pulnovo Medical, a rising star in the realm of ...

Akura Medical, a Shifamed portfolio company focused on venous thromboembolism care, announced recently that the FDA has approve ...

Merck & Co. said Friday that Canada's Drug Agency recommended the company's Winrevair for reimbursement as a treatment for adults with pulmonary arterial hypertension. The agency recommended the ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that Canada's Drug Agency (CDA) has ...

In patients with PAH, reducing peripheral serotonin using rodatristat ethyl negatively affects pulmonary hemodynamics and cardiac function.

Adding Uptravi (selexipag) to standard-of-care PAH treatment within six months may reduce the risk of hospitalization, per a ...

Addressing sleep-related complaints may enhance symptomatic treatment and management of PAH. Most patients with pulmonary arterial hypertension (PAH) suffered from poor sleep quality, and dyspnea was ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and ...

Keros Therapeutics (KROS – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Andrew ...